Patricia Murray uncovers the business secrets of the Nobelist Martin Evans and his partner Ajan Reginald. It seems the magic iMP cells used to treat patients in Greece were drawn from the blood of patients in Swansea, for the purpose of a secret PhD thesis. There is no serious science behind it, only serious investor money and a fraudulent patent.
Sir Martin Evans, winner of Nobel prize 2007, founded in 2009 the stem cell start-up Celixir, together with a struck-off dentist Ajan Reginald. With the help of the British heart surgeon Stephen Westaby, they ran a very profitable clinical trial in Greece, which now moved into UK.
The 2008 Lancet paper of Paolo Macchiarini and Martin Birchall about the world first trachea transplant might end up retracted. Until recently, the journal’s editor Richard Horton used to ignore and suppress “non peer-reviewed” evidence, but due to combined pressure of activism, media and politics, things started to move.
Videregen, the Liverpool-based company which bought the trachea regeneration patent from UCL, deployed lawyers against the academics Patricia Murray and Raphael Levy, precisely via their employer University of Liverpool. Main issue is the parliamentary submission by Levy and Murray, subject to absolute privilege. Yet Videregen also cites from the confidential notice of suspected research misconduct Murray and Levy submitted in good faith to UCL.